Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said. Dr.

Maharashtra CM reviews GBS cases, instructs officials for treatment arrangements, and coverage under MJPJAY in government ...

When you think about infectionsclassically the thought runs to malariawith recent cases also in Italy, tuberculosis or HIV ...

Pune reported nine suspected new cases of Guillain-Barre Syndrome (GBS), raising the city's total to 110 cases. Health officials have noted gender distribution, ventilator usage, and are conducting ...

Pune is battling a growing health crisis as Guillain-Barre Syndrome (GBS), a rare immunological nerve disorder, has gripped ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.